This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 18, 2020
Johnson & Johnson Starts Second Global Phase III Clinical Trial of Janssen COVID-19 Vaccine
Author(s)BioPharm International Editors
A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.
Advertisement
A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735, Janssen’s investigational vaccine candidate for the prevention of COVID-19, has been initiated by Johnson & Johnson.
According to a Nov. 15, 2020 press release, the ENSEMBLE 2 clinical trial will complement the ENSEMBLE trial, which is still enrolling and vaccinating study participants. The ENSEMBLE 2 trial is a randomized, double-blind, placebo-controlled clinical trial that has been designed to assess whether a two-dose vaccine regimen is safe and effective in adults versus placebo.
The company aims to enroll participants in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the United Kingdom, and the United States in its ENSEMBLE 2 trial. Additionally, the ENSEMBLE 2 trial is being conducted in collaboration with the UK National Institute for Health Research.
Both Phase III clinical trials, assessing a single-dose regimen and two-dose regimen, follow positive interim study results from an ongoing Phase I/IIa clinical study, which is investigating the safety profile and immunogenicity of both a single-dose and two dose vaccination.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5